[1 of 3]

Hosted by Joseph H. Schwab, MD and Matthew L. Goodwin, MD, PhD, this episode by the Section on Spine Oncology discusses the question, "Why do we want to be concerned about systemic disease and predict survival?"

The hosts review the concept of predictive modeling for spinal metastases and include discussion on NOMs and SINs criteria, reviewing the strengths and weaknesses of each and finishing up the talk by using the NOMs criteria to discuss systemic disease.

Disclosures:

Goodwin, Matthew L.: Consulting: Augmedics (A); Fellowship Support: AO Spine  (Salary, Fellowship Support), NREF (Salary, Fellowship Support); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement).

Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (None); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement), Stryker Spine (B, Outside 12-Month Requirement).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+